Ianalumab (VAY736) clinical trials

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

This study looks at the long-term safety and effectiveness of a new medicine, ianalumab, for people with Sjögren's Syndrome. It's for those who have already completed an earlier study and aims to see how well the treatment works and if it has any long-term side effects.